Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.50 NOK
979.00 K NOK
500.66 M NOK
23.65 M
About PHOTOCURE ASA
Sector
Industry
CEO
Daniel Schneider
Website
Headquarters
Oslo
Founded
1993
ISIN
NO0010000045
FIGI
BBG000CQ2XB1
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. Its products include Metvix for nonmelanoma skin cancer, Hexvix/Cysview for better detection and management of bladder cancer, and Cevira which is a photodynamic drug-device combination product for non-surgical treatment of high-grade cervical dysplasia. The company operates through the Commercial Franchise and Development Portfolio segments. The Commercial Franchise segment includes the sale of Hexvix/Cysview in the U.S. and Europe and other sales from partners and other products. The Development Portfolio segment focuses on the development of pipeline products. The company was founded in 1997 and is headquartered in Oslo, Norway.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PHO is 48.40 NOK — it has decreased by −2.52% in the past 24 hours. Watch PHOTOCURE ASA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OSL exchange PHOTOCURE ASA stocks are traded under the ticker PHO.
PHO stock has fallen by −8.33% compared to the previous week, the month change is a −3.20% fall, over the last year PHOTOCURE ASA has showed a −1.43% decrease.
We've gathered analysts' opinions on PHOTOCURE ASA future price: according to them, PHO price has a max estimate of 85.00 NOK and a min estimate of 84.00 NOK. Watch PHO chart and read a more detailed PHOTOCURE ASA stock forecast: see what analysts think of PHOTOCURE ASA and suggest that you do with its stocks.
PHO stock is 3.84% volatile and has beta coefficient of 0.27. Track PHOTOCURE ASA stock price on the chart and check out the list of the most volatile stocks — is PHOTOCURE ASA there?
Today PHOTOCURE ASA has the market capitalization of 1.31 B, it has decreased by −5.97% over the last week.
Yes, you can track PHOTOCURE ASA financials in yearly and quarterly reports right on TradingView.
PHOTOCURE ASA is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
PHO earnings for the last quarter are −0.13 NOK per share, whereas the estimation was −0.24 NOK resulting in a 46.90% surprise. The estimated earnings for the next quarter are 0.19 NOK per share. See more details about PHOTOCURE ASA earnings.
PHOTOCURE ASA revenue for the last quarter amounts to 120.10 M NOK, despite the estimated figure of 117.53 M NOK. In the next quarter, revenue is expected to reach 130.03 M NOK.
PHO net income for the last quarter is −3.47 M NOK, while the quarter before that showed 12.33 M NOK of net income which accounts for −128.11% change. Track more PHOTOCURE ASA financial stats to get the full picture.
No, PHO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 102.00 employees. See our rating of the largest employees — is PHOTOCURE ASA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHOTOCURE ASA EBITDA is 161.19 M NOK, and current EBITDA margin is 30.48%. See more stats in PHOTOCURE ASA financial statements.
Like other stocks, PHO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHOTOCURE ASA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHOTOCURE ASA technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHOTOCURE ASA stock shows the sell signal. See more of PHOTOCURE ASA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.